Join Now

Category Archives: BioUtah News

Owlet® Announces Strategic AI Partnership with webAI to Power the Next Generation of Personalized Infant Health and Sleep Insights

Strategic investment in private AI infrastructure positions Owlet to compound value from its growing base of proprietary infant wellness data.

| Tagged | Comments Off on Owlet® Announces Strategic AI Partnership with webAI to Power the Next Generation of Personalized Infant Health and Sleep Insights

Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies

Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies

| Comments Off on Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies

Behavioral Health Assessment Using Vocal Biomarkers

Behavioral Health Assessment Using Vocal Biomarkers

| Tagged | Comments Off on Behavioral Health Assessment Using Vocal Biomarkers

Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West

Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West

| Tagged | Comments Off on Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West

Owlet’s First Baby Sleep Report Analyzes Data from Over 1.2 Million Owlet Monitored Babies

Report draws on Owlet’s massive infant sleep dataset, one of the world’s largest, to reveal how babies sleep – evaluating bedtimes, wake-ups, sleep stretches, and biometric trends

| Tagged | Comments Off on Owlet’s First Baby Sleep Report Analyzes Data from Over 1.2 Million Owlet Monitored Babies

PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease

| Tagged | Comments Off on PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial

SPARC Health Announces Second Cohort Applications, Building on Inaugural Program Success

SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of Economic Opportunity (GOEO), announced applications are now open for its second cohort program.

Also posted in Newsletters | | Tagged | Comments Off on SPARC Health Announces Second Cohort Applications, Building on Inaugural Program Success

SPARC Health, BioUtah Co-Host Shark Tank-Style Pitch Competition at 2026 Wilson Sonsini Entrepreneur & Investor Life Sciences Summit

Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare companies with a premier platform to showcase innovations to experienced investors and industry leaders.

| Comments Off on SPARC Health, BioUtah Co-Host Shark Tank-Style Pitch Competition at 2026 Wilson Sonsini Entrepreneur & Investor Life Sciences Summit

JP Morgan Healthcare Conference Recap – Photo Gallery

Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.

| Tagged | Comments Off on JP Morgan Healthcare Conference Recap – Photo Gallery

Haemonetics to Acquire Vivasure Medical

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.

| Tagged | Comments Off on Haemonetics to Acquire Vivasure Medical

BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026

| Tagged | Comments Off on BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease

| Tagged | Comments Off on DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease